Boston Scientific CORP Form 4 insider transactions

Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific Corp, reported a transaction in 2,930 shares of common stock on August 11, 2026.

Jonathan Monson, EVP and CFO of Boston Scientific Corp, reported a transaction in 9,908 shares of common stock on August 10, 2026.

David C Habiger, a Director of Boston Scientific Corp, purchased 2,100 shares of common stock on August 5, 2026 for $47.59 per share.

Michael F Mahoney, Chairman, President & CEO and a Director of Boston Scientific Corp, purchased 186,240 shares of common stock on August 3, 2026 for $48.33 per share.

Boston Scientific EVP and CFO Jonathan Monson reported transactions involving restricted stock units and common stock.

Boston Scientific Director Cheryl Pegus purchased 1,770 shares of common stock at an average price of $56.49.

Boston Scientific Corporation Director Edward J. Ludwig acquired 3,580 shares of common stock at $56.68 per share.

Boston Scientific Director David C. Habiger purchased 4,450 shares of common stock across two transactions in May 2026.

Boston Scientific Corp. director Ellen M. Zane acquired 3,800 shares of common stock through an annual equity award.

Boston Scientific Director David S. Wichmann was granted an annual equity award of 3,800 shares of common stock, vesting upon the next annual meeting.

Christophe Pierre Weber, a Director at Boston Scientific Corp., reported the acquisition of restricted stock and deferred stock units valued at approximately $465,500.

Cathy R. Smith, a Director at Boston Scientific Corp., acquired deferred stock units valued at approximately $340,000 on May 7, 2026.

Cheryl Pegus, a Director at Boston Scientific, received annual equity awards in the form of deferred stock units on May 7, 2026.

Boston Scientific Director Susan E. Morano was granted restricted stock awards valued at approximately $287,500 on May 7, 2026, as part of her annual compensation.

Jessica L. Mega, a Director at Boston Scientific Corp., acquired 3,800 shares of common stock on May 7, 2026, as part of an annual equity award.

David C. Habiger, a Director at Boston Scientific Corp., acquired 3,800 shares of common stock on May 7, 2026, as part of an annual equity award.

Edward Ludwig, a Director at Boston Scientific Corp, reported the acquisition of 3,800 shares of common stock on May 7, 2026, as part of an annual equity award.

Boston Scientific Corp. executive Padraig Andrew O'Connor reported transactions involving company stock and restricted stock units.

Arthur C. Butcher, EVP & Group President, MedSurg & APAC at Boston Scientific, reported transactions involving restricted stock units and common stock.

Boston Scientific confirms its commitment to the Penumbra acquisition during its Q1 2026 earnings call, targeting a second-half 2026 close.

Boston Scientific Director Cheryl Pegus acquired 24 deferred stock units as part of her compensation, vesting at the next annual meeting.

Boston Scientific Director Susan E. Morano received a grant of 24 restricted common shares as part of her compensation, vesting at the next annual meeting.

Boston Scientific's new director, Christophe Pierre Weber, received restricted stock grants totaling 879 shares as part of his compensation package.

Boston Scientific Corp. director Cathy R. Smith was granted 879 deferred stock units as part of her compensation package, including an initial equity award and units in lieu of cash.

Boston Scientific's SVP, Global Controller and CAO, Emily Woodworth, reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Boston Scientific's EVP & Group President, Arthur C. Butcher, rebalanced his 401(k) holdings, acquiring 6,851 shares of common stock at $75.76 and disposing of 55,792 shares.

Boston Scientific reports strong Q4 2025 results, driven by cardiovascular growth, and reaffirms its long-term targets, emphasizing the strategic acquisition of Penumbra.

Boston Scientific's Chairman, President & CEO, Michael F. Mahoney, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-established 10b5-1 trading plan.

Boston Scientific announced its definitive agreement to acquire Penumbra for $14.5 billion in cash and stock, aiming to become a neurovascular leader.

Boston Scientific announced its definitive agreement to acquire Penumbra for $14.5 billion in cash and stock, aiming to become a neurovascular leader.